ARWR
Arrowhead Pharmaceuticals·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Revenue Decline
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ARWR
Arrowhead Pharmaceuticals, Inc.
A developer of RNAi interference and peptide drug conjugates for a wide range of diseases
Biological Technology
Invalid Date
08/27/2004
NASDAQ Stock Exchange
609
09-30
Common stock
177 E. Colorado Blvd, Suite 700, Pasadena, California 91105
--
Arrowhead Pharmaceuticals, Inc., originally incorporated in South Dakota in 1989, was re-incorporated in Delaware. The company develops drugs to treat intractable diseases by silencing the genes of diseases. Using a wide range of RNA chemical combinations and highly efficient delivery modes, the company's therapies trigger RNA interference mechanisms to induce rapid, deep and persistent knockdown of target genes. The company has focused its resources on therapies that exclusively utilize its high levels of pharmacological activity in multiple animal models across multiple therapeutic areas.
Earnings Call
Q2/2025
Estimate EPS-0.46
Actual EPS2.75
Estimate Revenue116.27M
Actual Revenue542.71M
Arrowhead Pharmaceuticals' Q2 2025: Contradictions in Plazasiran Strategy, Obesity Programs, and Pancreatitis Risk
May 20,2025 06:21
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ARWR has released its 2025 Q3 earnings. EPS was reported at -1.26, versus the expected -1.1, missing expectations. The chart below visualizes how ARWR has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ARWR has released its 2025 Q3 earnings report, with revenue of 27.77M, reflecting a YoY change of NaN%, and net profit of -178.65M, showing a YoY change of -2.69%. The Sankey diagram below clearly presents ARWR's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
